Benralizumab for allergic asthma: a randomised, double-blind, placebo-controlled, trial.
Gail M GauvreauRoma SehmiJ Mark FitzGeraldRichard LeighDonald W CockcroftBeth E DavisIrvin MayersLouis-Philippe BouletDhuha Al-SajeeBrittany M SalterRuth CusackTerence N HoChristiane WhetstoneNadia AlsajiImran SatiaKieran J KillianPatrick D MitchellIain P MageeCeline BergeronMohit BhutaniViktoria WerkströmTomasz DurżyńskiKathryn ShoemakerRohit K KatialMaria JisonPaul NewboldChristopher McCraePaul M O'ByrnePublished in: The European respiratory journal (2024)
Benralizumab administration over 8 weeks resulted in a significant attenuation of blood, bone marrow and sputum eosinophilia in participants with mild allergic asthma; however, there was no change in the LAR, suggesting that eosinophils alone are not a key component of allergen-induced bronchoconstriction.
Keyphrases
- allergic rhinitis
- double blind
- placebo controlled
- bone marrow
- clinical trial
- study protocol
- chronic obstructive pulmonary disease
- lung function
- cystic fibrosis
- phase iii
- mycobacterium tuberculosis
- mesenchymal stem cells
- open label
- high glucose
- phase ii
- diabetic rats
- randomized controlled trial
- pulmonary tuberculosis
- atopic dermatitis